---
title: "Fennec Pharmaceuticals repays $13 million of convertible debt early"
url: "https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-12-20"
section: "Financings"
tickers: "NASDAQ:FENC"
source: "https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_ex99-1.htm"
summary: "The payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares."
---

By the aibio.space news desk.

Sources

- [Fennec Pharmaceuticals Inc. 8-K (2024-12-20)](https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_ex99-1.htm)

[FENC](https://aibio.space/companies/fennec-pharmaceuticals/)

2024-12-20

# Fennec Pharmaceuticals repays $13 million of convertible debt early

Tickers [FENC](https://aibio.space/companies/fennec-pharmaceuticals/)

The payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares.

## Key facts

- **Company**: Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

- **News type**: Financings

- **Primary source**: [Fennec Pharmaceuticals Inc. 8-K (2024-12-20)](https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_ex99-1.htm)

*A city skyline in morning haze. CC0, via rawpixel. The picture shows the field, not the companies named.*

Fennec Pharmaceuticals Inc. (Nasdaq: [FENC](https://aibio.space/companies/fennec-pharmaceuticals/)) repaid $13 million of its approximately $32 million convertible debt facility with Petrichor Healthcare Capital Management ahead of schedule.

After the payment, the facility stands at approximately $19 million and still matures in September 2027. Fennec said the repayment was financed entirely with available cash, according to its [press release](https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_ex99-1.htm).

Convertible debt is debt that can be turned into shares. Fennec said the early repayment eliminates approximately $1.5 million in annual interest expense and a potential equity overhang of approximately 1.6 Million Shares.

Chief Executive Officer Jeff Hackman said the move "optimizes the Company's balance sheet and overall capital structure" while saving future interest payments.

The company said it still expects its cash, cash equivalents and investment securities to fund planned operations into 2026, as it reported with its third quarter 2024 results.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

FENC

Fennec Pharmaceuticals Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Fennec Pharmaceuticals repays $13 million of convertible debt early", 2024-12-20, https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/